From Canada SETTING: Capital Health Tuberculosis (TB) Clinic, Edmonton, Alberta, Canada. OBJECTIVE: To analyze the QuantiFERON-TB Gold In-Tube test (QFT) results after implementation as a routine test for tuberculin skin test (TST) positive patients. DESIGN: From November 2004 until January 2007, patients who were TST-positive and were eligible for preventive treatment based on Canadian guidelines, were offered a QFT. RESULTS: Of 1446 TST-positive patients, only 566 (39.6%) were QFT-positive. Categorized by reason for TST testing, 43.1% of 304 contacts, 32.8% of 348 employment screens and 24.2% of 298 post secondary school screens were QFT-positive. In contrast, 59.7% of 290 immigration screens were QFT-positive. A multivariate analysis found that QFT positivity was associated with older age, larger TST size, high-incidence TB region of birth, history of TB and chest X-ray findings suggestive of previous TB. CONCLUSION: Implementation of the QFT as a secondary test for latent TB infection (LTBI) can significantly reduce the number of patients given LTBI treatment in a low-incidence country such as Canada.
Regards,
- Forums
- ASX - By Stock
- CST
- some light reading
some light reading, page-71
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CST (ASX) to my watchlist
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online